Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024 Sep 18;29(1):464.
doi: 10.1186/s40001-024-02046-5.

Clinical efficacy and safety of faecal microbiota transplantation in the treatment of irritable bowel syndrome: a systematic review, meta-analysis and trial sequential analysis

Shao-Wei Lo #  1 , Tsung-Hsuan Hung #  1 , Yen-Tsen Lin  1 , Chun-Shen Lee  1 , Chiung-Yu Chen  1   2 , Ching-Ju Fang  3   4 , Pei-Chun Lai  5   6
Affiliations
Meta-Analysis

Clinical efficacy and safety of faecal microbiota transplantation in the treatment of irritable bowel syndrome: a systematic review, meta-analysis and trial sequential analysis

Shao-Wei Lo et al. Eur J Med Res. .

Abstract

Background: The aim of this study is to evaluate the efficacy and safety of faecal microbiota transplantation (FMT) for the treatment of irritable bowel syndrome (IBS).

Methods: We searched four databases for randomised controlled trials (RCTs) that compared FMT with a control intervention in patients with IBS. The revised Cochrane risk-of-bias (RoB) tool was chosen for appraisal. Meta-analysis with trial sequential analysis (TSA) was conducted. Grading of Recommendations Assessment Development and Evaluation (GRADE) methodology was used to assess the certainty of evidence (CoE).

Results: We included 12 RCTs with a total of 615 participants. Meta-analyses showed no significant difference between the FMT and control groups in terms of clinical responses (relative risk [RR] = 1.44, 95% confidence interval [CI] 0.88-2.33) and changes in IBS Severity Scoring System (IBS-SSS) scores (standardised mean difference [SMD] = - 0.31, 95% CI - 0.72 to 0.09) and IBS Quality of Life (IBS-QOL) scores (SMD = 0.30, 95% CI - 0.09 to 0.69). Subgroup analysis revealed that in studies with low RoB and using endoscopy, nasojejunal tube and rectal enema delivery, FMT led to a significant improvement in clinical responses and changes in IBS-SSS and IBS-QOL scores. TSA suggested that the current evidence is inconclusive and that the CoE is very low.

Conclusion: This study suggests that patients with IBS may benefit from FMT especially when it is administered via endoscopy, nasojejunal tube or rectal enema. However, the certainty of evidence is very low. Further research is needed to confirm the efficacy and safety of FMT for IBS treatment.

Trial registration: PROSPERO registration number CRD42020211002.

Keywords: Faecal microbiota transplantation; Irritable bowel syndrome; Meta-analysis; Randomised controlled trial; Systemic review.

PubMed Disclaimer

Conflict of interest statement

The authors report there are no competing interests to declare.

Figures

Fig. 1
Fig. 1
PRISMA 2020 flow diagram of study selection
Fig. 2
Fig. 2
Forest plot of the clinical responses of patients with IBS to FMT or the placebo. a Subgroup analysis based on the route of FMT delivery. b Subgroup analysis based on the RoB of a study. c TSA of the FMT treatment effect on patients with IBS
Fig. 3
Fig. 3
Forest plot of the change in the IBS-SSS of patients with IBS in response to FMT or the placebo. a Subgroup analysis based on the route of FMT delivery. b Subgroup analysis based on the RoB in a study
Fig. 4
Fig. 4
Forest plot of the change in the IBS-QOL of patients with IBS in response to FMT or the placebo. a Subgroup analysis based on the route of FMT delivery. b Subgroup analysis based on the RoB of a study
Fig. 5
Fig. 5
Forest plot of the adverse events in patients with IBS in response to FMT or the placebo: a abdominal pain, b bloating/flatulence, c constipation, d diarrhea, e fever, f nausea
See this image and copyright information in PMC

References

    1. Lacy BE, Mearin F, Chang L, Chey WD, Lembo AJ, Simren M, et al. Bowel disorders. Gastroenterology. 2016;150(6):1393–407. - PubMed
    1. Sperber AD, Dumitrascu D, Fukudo S, Gerson C, Ghoshal UC, Gwee KA, et al. The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a Rome Foundation working team literature review. Gut. 2017;66(6):1075–82. - PubMed
    1. Glynn E, Galambosi G, Boland K. Resolution of weight loss, systemic illness, and fever after triple therapy: a surprising response to treatment of positive urease test. Gastroenterology. 2021;160(5):e1–3. - PubMed
    1. Kim KO, Gluck M. Fecal microbiota transplantation: an update on clinical practice. Clinical endoscopy. 2019;52(2):137–43. - PMC - PubMed
    1. Staley C, Khoruts A, Sadowsky MJ. Contemporary applications of fecal microbiota transplantation to treat intestinal diseases in humans. Arch Med Res. 2017;48(8):766–73. - PubMed

MeSH terms

LinkOut - more resources